<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112793">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125266</url>
  </required_header>
  <id_info>
    <org_study_id>V4041</org_study_id>
    <nct_id>NCT02125266</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy Study of V404 PDS in Uveitis</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forsight Vision4</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forsight Vision4</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the safety of V404 PDS in patients with chronic
      non-infectious uveitis. Secondarily, the study will evaluate whether V404 PDS can provide
      clinically measurable benefit over an extended period of time in patients with chronic
      non-infectious uveitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vitreous haze score</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in macular thickness by ocular coherence tomography</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Uveitis, Posterior</condition>
  <condition>Uveitis, Intermediate</condition>
  <arm_group>
    <arm_group_label>Low Dose V404 PDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose V404 PDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V404</intervention_name>
    <description>Sustained Release</description>
    <arm_group_label>Low Dose V404 PDS</arm_group_label>
    <arm_group_label>High Dose V404 PDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Confirmed diagnosis of active uveitis

          -  Sufficient lens/media clarity

          -  Meet best-corrected visual acuity criteria

          -  Willing and able to use contraception

        Exclusion Criteria:

          -  Pregnant, breast feeding

          -  Uncontrolled glaucoma

          -  Intraocular surgery or periocular/intraocular injections within 6 weeks

          -  Periocular or intraocular steroid within 3 months

          -  Prior vitrectomy

          -  Prior corneal transplant

          -  Prior fluocinolone implant

          -  Allergy or sensitivity to study drug

          -  Participation in other trial within 30 days

          -  Abnormal liver function

          -  History of positive serum tuberculosis test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Signe Erickson, PhD</last_name>
    <phone>650-223-8103</phone>
    <email>serickson@fsv4.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Chorioretinitis</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
